tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Caufield, 55 are a BUY (98.21%), 1 are a HOLD (1.79%).
Analyst Matthew Caufield, currently employed carries an average stock price target met ratio of 11.67% that have a potential upside of 10.11% achieved within 29 days. Previously, Matthew Caufield worked at HC WAINWRIGHT.
Matthew Caufield’s has documented 111 price targets and ratings displayed on 10 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on FDMT, 4D Molecular Therapeutics at 14-Nov-2024.
Analyst best performing recommendations are on ISEE (IVERIC BIO).
The best stock recommendation documented was for GMTX (GEMINI THERAPEUTICS) at 12/15/2021. The price target of $20 was fulfilled within 34 days with a profit of $9.9 (33.11%) receiving and performance score of 9.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$10
$5.76 (135.85%)
$10
3 months 11 days ago
(09-Aug-2024)
0/9 (0%)
$4.9 (96.08%)
Buy
$8
$3.76 (88.68%)
$25
1 years 1 months 3 days ago
(17-Oct-2023)
0/10 (0%)
$6.16 (334.78%)
Hold
$14
1 years 1 months 3 days ago
(17-Oct-2023)
2/3 (66.67%)
$6.42 (84.70%)
362
Buy
2 years 10 months 25 days ago
(27-Dec-2021)
0/1 (0%)
$9.48 (75.72%)
Buy
$20
$15.76 (371.70%)
$20
5 years 4 months 25 days ago
(26-Jun-2019)
0/4 (0%)
$13.77 (221.03%)
Which stock is Matthew Caufield is most bullish on?
Which stock is Matthew Caufield is most reserved on?
What Year was the first public recommendation made by Matthew Caufield?
